Previous 10 | Next 10 |
The shares of clinical-stage biotech Caladrius Biosciences (NASDAQ:CLBS) have added ~29% in the pre-market Wednesday in reaction to a merger agreement with the privately held Cend Therapeutics. Per the terms, Cend will merge with a subsidiary of Caladrius (CLBS) in an all-stock deal...
Combined company to be renamed Lisata Therapeutics upon transaction closing Combination will create a financially sound Nasdaq-listed company with a diverse product development pipeline, strong existing partnerships and potential for future attractive partnerships Lisata to combin...
Caladrius Biosciences (NASDAQ:CLBS) said the first patient was treated in a phase 1b trial of CLBS201 to treat diabetic kidney disease (DKD) The company said CLBS201 is an investigational autologous CD34+ cell therapy for administration directly into the renal artery to reverse or slow the de...
BASKING RIDGE, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse di...
Caladrius Biosciences, Inc. (CLBS) Q4 2021 Earnings Conference Call March 22, 2022 4:30 PM ET Company Participants John Menditto – Vice President-Investor Relations and Corporate Communications David Mazzo – President and Chief Executive Officer James Nisco – Vice Preside...
Caladrius Biosciences press release (NASDAQ:CLBS): Q4 GAAP EPS of -$0.11. As of Dec. 31, 2021, we had cash, cash equivalents and marketable securities of approximately $95M. For further details see: Caladrius Biosciences GAAP EPS of -$0.11
BASKING RIDGE, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease...
Caladrius Biosciences (NASDAQ:CLBS) is scheduled to announce Q4 earnings results on Monday, March 21st, after market close. The consensus EPS Estimate is -$0.15 and the consensus Revenue Estimate is $0M For further details see: Caladrius Biosciences Q4 2021 Earnings Preview
ADBE, AIR, APTO, AVGR, CLBS, GAN, HQY, OTCQB:NEXCF, PAGS, PAYS, POSH, SLDP, WOR, ZY For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Tuesday's close
BASKING RIDGE, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease...
News, Short Squeeze, Breakout and More Instantly...
Caladrius Biosciences Inc. Company Name:
CLBS Stock Symbol:
NASDAQ Market:
Caladrius Biosciences Inc. Website:
BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of ...
NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Conference to be held on September 15 th . Individual investors, institutional ...
BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced tha...